Nilo Therapeutics closed a $101 million Series A to develop small‑molecule drugs that target neural circuits regulating systemic inflammation. The preclinical startup was founded on neuro‑immunology discoveries from Charles Zuker, Ruslan Medzhitov and Steve Liberles and will translate vagal and brain‑stem circuitry insights into orally available modulators of immunologic set points. The round was led by The Column Group, DCVC Bio and Lux Capital with participation from the Gates Foundation and Alexandria Venture Investments. Nilo plans to establish labs in New York, expand its R&D team, and advance multiple preclinical programs aimed at autoimmune and inflammatory diseases. The financing and scientific pedigree underscore a growing industry interest in therapies that act on neuro‑immune axes rather than traditional immune checkpoints or cytokine targets.